Chat with us, powered by LiveChat

+91-80-26860424 / 34

Call Us Today

LinkedIn

Search
 

Pharmaceuticals Tag

BananaIP Counsels > Posts tagged "Pharmaceuticals"

A Pharmaceutical Perspective by Ms. Vinita Radhakrishnan

The featured image shows a stick figure standing on two diverging arrows. While the arrow on the left reads trade secrets, the arrow on the right reads patents. To know more about this post click here.

This talk on Trade Secrets and Patents was delivered by Ms. Vinita Radhakrishnan at the IIPLA 5th IP Conference held at the Carlton Palace Hotel, Dubai, United Arab Emirates (UAE). You may view the full presentation below. [slideshare id=130475180&doc=iiplapresentation-190204133117] Topics Covered in the presentation include: 1. The shift from traditional medicine to modern medicine 2. Making a choice between patents and trade secrets 3. Pros and Cons of Trade Secrets and Patents 4. IP Protection Models 5. Invention based IP strategy 6. Industry based IP strategy 7. Industry Trends 8. Top 10 pharma companies and their patenting trends 9. Patent trends (decrease in patents filed) 10. Number of patent applications filed by pharma...

Continue reading

Indian Herbal Viagra Receives Patent Grant

First Publication Date: 5th October 2010 Kunnath Pharmaceuticals, Kerala recently received a patent for their product, Musli Power Xtra, an Indian herbal aphrodisiac for men and women. Musli Power Xtra popularly known as the ‘Indian Herbal Viagra’ is  reportedly India’s first ayurvedic herbal formulation to receive a patent for the treatment of sexual dysfunction. The herbs and ingredients which form part of the formulation includes the following: Chlorophylum borivillianum (Safed Musli), Mucuna purita, Withania somnifera, Moringa oleifera, Embilica officinalis, Tribulus trerrestris, Hygrophilla auriculata, Myristica fragrans. The patent (patent no. 241602) has been granted for the application titled “Herbal formulation used as a health...

Continue reading

UNDP Issues Guidelines For Pharmaceutical Patent Examination

The featured image shows a person holding some white pills in his fist, which is half open. The post is about recent guidelines issued by the UNDP regarding examination of Pharma Patents. To know more, please click here.

The United Nations Development Programme (UNDP) has recently published guidelines for examination of patent applications relating to pharmaceuticals.The guidelines have highlighted the need for examining pharmaceutical patents from the perspective of public health.The guidelines set by Prof. Carlos M Correa strongly recommend nations to set out specific and more stringent standards for pharmaceutical patents. The guidelines also encourage patent offices to exploit the flexibilities allowed by the TRIPS Agreement with regard to the aforementioned guidelines. In his foreword, Mandeep Dhaliwal, Director HIV, Health and Development Group, UNDP stated, “Recognizing the key role that patent offices and patent examiners play in...

Continue reading

‘Killead’s Patent Application Killed by the Indian Patent Office!

This image depicts a person holding a placard reading GILEAD 1,000 per Pill, Shame. This image is relevant as Gilead had filed for a patent for the same medicine in India for the same price. Click on the image for more information

Gilead Sciences was rejected patent for its blockbuster drug Sofosbuvir, a new Hepatitis C drug by the India Patent Office in a major decision taken on 13 January 2015. The drug is branded under the name Sovaldi. Gilead had priced the drug at US$84,000 for a treatment course, or $1,000 per pill in the US and had received a regulatory approval in US in 2013. The patent application (6087/DELNP/2005) for the drug was opposed by the Indian generic company Natco; Medicines, Access & Knowledge a non-profit initiative; and the Delhi Network of Positive People (DNP+) pointing out that the drug does...

Continue reading

Drug Humira turns Rheumatic for Abbott Biotechnology

The image depicts some tablets inside a glass. This image is relevant as Drug Humria was not granted Patent in India. Click on the image for more information

The Indian Patent Office on December 31, 2014 set aside its order of granting a Patent to Abbott Biotechnology for its drug, Humira, in light of pre-grant opposition filed by Glenmark Pharmaceuticals. In November, 2003, Abbott had filed a patent application No. 526/DELNP/2005 for its drug named Humira, a formulation of human antibodies for treating Rheumatoid Arthritis. Glenmark filed a pre-grant opposition to this application in September, 2008. Since this was not brought to the notice of the Controller, Patent No. 234,555 was granted to said invention in June, 2009. In July, 2009, this discrepancy was brought to the notice of...

Continue reading
css.php
Speak with an IP Expert Today
close slider